Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | F2 | P00734 | 1/20 | 0.60 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.60 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15846529 | 1.00 | F10 (0.69) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21278418 | 0.87 | F10 (0.73) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL18155440 | 0.86 | F10 (0.69) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14838785 | 0.86 | F10 (0.72) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15120924 | 0.86 | F10 (0.72) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13575721 | 0.86 | F10 (0.72) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL806187 | 0.84 | F10 (0.74) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2196287 | 0.83 | F10 (0.67) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2196290 | 0.83 | F10 (0.67) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16467069 | 0.83 | F10 (0.73) | F10CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2895176-B1 | RIVAROXABAN INTERMEDIATE AND PREPARATION THEREOF | WANBURY LTD (IN) | 2016-10-19 | — | — | EP | disclosed |
| US-9394292-B2 | Rivaroxaban intermediate and preparation thereof | WANBURY LTD. (IN) | 2016-07-19 | — | — | US | disclosed |
| US-9394292-B2 | Rivaroxaban intermediate and preparation thereof | WANBURY LTD. (IN) | 2016-07-19 | — | — | US | disclosed |
| US-20150299175-A1 | RIVAROXABAN INTERMEDIATE AND PREPARATION THEREOF | WANBURY LTD. (IN) | 2015-10-22 | — | — | US | disclosed |
| US-20150299175-A1 | RIVAROXABAN INTERMEDIATE AND PREPARATION THEREOF | WANBURY LTD. (IN) | 2015-10-22 | — | — | US | disclosed |
| WO-2014102820-A2 | RIVAROXABAN INTERMEDIATE AND PREPARATION THEREOF | WANBURY LTD. (IN) | 2014-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299175-A1 | RIVAROXABAN INTERMEDIATE AND PREPARATION THEREOF | VKORC1L1, VKORC1, CYP3A5 | F10 27/4885CYP1A2 19/4885CYP3A4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.